Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
作者信息
Uprety Dipesh
机构信息
Thoracic Oncology, Karmanos Cancer Institute, Detroit, Michigan.
出版信息
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
PMID:33641721
Abstract
摘要
相似文献
1
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
2
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021 Feb;16(2):e12-e14. doi: 10.1016/j.jtho.2020.10.016.
3
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
J Thorac Oncol. 2021 Mar;16(3):368-370. doi: 10.1016/j.jtho.2020.11.027.
4
Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation.
Lung Cancer. 2020 Dec;150:247-248. doi: 10.1016/j.lungcan.2020.09.019. Epub 2020 Sep 28.
5
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.
J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.
6
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021 Feb;16(2):e14. doi: 10.1016/j.jtho.2020.12.009.
7
Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.
Ann Pharmacother. 2022 Apr;56(4):503-504. doi: 10.1177/10600280211036909. Epub 2021 Aug 3.
8
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.
J Thorac Oncol. 2020 Mar;15(3):e46-e48. doi: 10.1016/j.jtho.2019.11.018.
9
Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Future Oncol. 2021 Jul;17(19):2513-2527. doi: 10.2217/fon-2021-0356. Epub 2021 May 14.
10
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
Cancer. 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10.
引用本文的文献
1
Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse.
Tuberc Respir Dis (Seoul). 2023 Jan;86(1):14-22. doi: 10.4046/trd.2022.0081. Epub 2022 Oct 26.
2
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Clin Transl Oncol. 2023 Jan;25(1):283-291. doi: 10.1007/s12094-022-02941-5. Epub 2022 Sep 27.
3
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA NSCLC (Except with Alterations?) When Adopting Adjuvant Osimertinib.
Lung Cancer (Auckl). 2022 Apr 26;13:23-31. doi: 10.2147/LCTT.S358902. eCollection 2022.
4
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer.
World J Clin Oncol. 2021 Oct 24;12(10):912-925. doi: 10.5306/wjco.v12.i10.912.
Zotero 插件